SCHEMBL6155360

SCHEMBL6155360

CCCOc1cc(NC2CCNCC2)ccc1C(N)=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
HSD17B10 Q99714 2/20 0.46
MEN1 O00255 1/20 0.41
NR1I2 O75469 1/20 0.41
LMNA P02545 1/20 0.41
CHRM2 P08172 1/20 0.41
CYP3A4 P08684 1/20 0.41
ADRA2A P08913 1/20 0.41
OPRK1 P41145 1/20 0.41
HTR2B P41595 1/20 0.41
SLC6A3 Q01959 1/20 0.41
KMT2A Q03164 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
AURKA O14965 1/20 0.41
RPS6KB1 P23443 1/20 0.41
SYK P43405 4/20 0.40
P2RX7 Q99572 1/20 0.39
PARP15 Q460N3 1/20 0.38
PARP10 Q53GL7 1/20 0.38
KIT P10721 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6153513 0.91 SYK (0.46) MAPTMEN1SLC6A3KMT2AAURKA
SCHEMBL6153679 0.84 HTR4 (0.48) MEN1LMNAKMT2AAURKARPS6KB1
SCHEMBL6154413 0.81 IRAK4 (0.48) MKNK1MKNK2
SCHEMBL6154140 0.81 HTR4 (0.45) OPRK1RPS6KB1SYKPARP15PARP10
SCHEMBL6155471 0.79 LTA4H (0.50) MEN1CYP3A4ADRA2AOPRK1HTR2B
SCHEMBL6153310 0.79 EPHX1 (0.48) AURKARPS6KB1SYKP2RX7KIT
SCHEMBL6155049 0.78 FLT3 (0.44) MEN1KMT2AAURKARPS6KB1SYK
SCHEMBL6153421 0.76 AURKA (0.45) AURKARPS6KB1SYKP2RX7FLT3
SCHEMBL6156769 0.75 ROCK2 (0.47) AURKARPS6KB1SYKP2RX7PARP15
SCHEMBL6153710 0.75 RPS6KB1 (0.44) AURKARPS6KB1SYKP2RX7FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 US disclosed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182040-A1 Benzamide derivatives ROCK1, ROCK2, NHERF1 MAPT 4237/4885HSD17B10 1176/4885MEN1 1993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.